Vertex Pharmaceuticals

863 articles about Vertex Pharmaceuticals

• Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences

  6/1/2010

• Vertex Pharmaceuticals (MA) Hepatitis C Drug, Telaprevir Achieves 75% Cure Rate in Study

  5/26/2010

• Shareholders of Vertex Pharmaceuticals (MA) Approve Proxy Proposals at Annual Meeting

  5/13/2010

• Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences

  4/28/2010

• Vertex Pharmaceuticals (MA) Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress

  4/22/2010

• Vertex Pharmaceuticals (MA): 59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection

  4/15/2010

• Vertex Pharmaceuticals (MA)'s Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial

  4/15/2010

• Vertex Pharmaceuticals (MA): The New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy

  4/8/2010

• Vertex Pharmaceuticals (MA) Announces Webcast of its Presentation at Canaccord Adams' Hepatitis C Conference

  3/31/2010

• Vertex Pharmaceuticals (MA) Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting

  3/17/2010

• Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences

  3/12/2010

• Vertex Pharmaceuticals (MA) Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies

  3/1/2010

• Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences

  2/26/2010

• Vertex Pharmaceuticals (MA) Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013

  2/17/2010

• Vertex Pharmaceuticals (MA) Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs

  2/5/2010

• Vertex Pharmaceuticals (MA) Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis

  2/3/2010

• Vertex Pharmaceuticals (MA)'s Matt Emmens on His Journey From Security Guard to CEO

  1/28/2010

• Vertex Pharmaceuticals (MA) Announces the Date of its Full Year 2009 Financial Results Conference Call and Webcast

  1/21/2010

• Vertex Pharmaceuticals (MA) Announces Webcast of its Presentation at the 28th Annual J.P. Morgan Healthcare Conference

  1/5/2010

• Vertex Pharmaceuticals (MA) Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer

  12/10/2009